Valneva (NASDAQ:VALN) Shares Gap Down – Time to Sell?

Valneva SE Sponsored ADR (NASDAQ:VALN)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $6.30, but opened at $5.89. Valneva shares last traded at $5.9640, with a volume of 4,518 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Wall Street Zen lowered Valneva to a “strong sell” rating in a report on Saturday, April 25th. Guggenheim set a $11.00 price objective on Valneva in a research note on Thursday, April 16th. Finally, The Goldman Sachs Group cut shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 target price on the stock. in a report on Wednesday, April 22nd. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $11.98.

Valneva Stock Down 6.7%

The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.85 and a current ratio of 2.38. The company has a market capitalization of $506.40 million, a PE ratio of -3.72 and a beta of 1.72. The firm’s 50-day simple moving average is $7.48 and its 200 day simple moving average is $8.69.

Valneva (NASDAQ:VALN) last issued its earnings results on Sunday, February 15th. The company reported ($0.68) earnings per share for the quarter. The company had revenue of $55.92 million for the quarter. Valneva had a negative return on equity of 76.81% and a negative net margin of 67.64%. As a group, equities research analysts forecast that Valneva SE Sponsored ADR will post -0.81 earnings per share for the current year.

Institutional Trading of Valneva

Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Valneva in the fourth quarter valued at $44,000. Marex Group plc acquired a new stake in shares of Valneva in the second quarter worth approximately $64,000. XTX Topco Ltd acquired a new position in Valneva in the fourth quarter valued at $94,000. VSM Wealth Advisory LLC grew its stake in Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after buying an additional 5,000 shares during the period. Finally, JPMorgan Chase & Co. purchased a new position in shares of Valneva in the 3rd quarter valued at $124,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.